StockGuide AI - assistente per la ricerca di mercato

Gli analisti di Carter Worth raccomandano di acquistare azioni Incyte (INCY) mentre esce da un intervallo di sette mesi

06/26/2026, 11:37 AM investing recommendation Analysts: analysts, Carter Worth biotech

Incyte, un'azienda biofarmaceutica, è pronta per un potenziale breakout dopo essere stata stagnante per sette mesi, con gli analisti che suggeriscono un outlook rialzista mentre mira a superare il limite di $125.

Gli analisti di UBS hanno abbassato il target di prezzo di Zealand Pharma (ZEAL) a 540 corone danesi a causa di preoccupazioni sulla tollerabilità di survodutide

06/18/2026, 10:36 PM business rating_drop Analysts: analysts, UBS biotech

Le azioni di Zealand Pharma hanno subito un notevole calo dopo dati deludenti sul suo farmaco per la perdita di peso survodutide, portando gli analisti a ridurre le previsioni di vendita e a concentrare l'attenzione sul suo altro farmaco, petrelintide, che potrebbe offrire migliori prospettive nel mercato dell'obesità.

Gli analisti di JPMorgan evidenziano la riapertura del mercato IPO biotech in mezzo a un'attività continua di M&A da parte delle Big Pharma

06/15/2026, 10:36 PM business review Analysts: analysts, JPMorgan biotech healthcare

Il settore biotech sta vivendo una ripresa nell'attività del mercato pubblico, ma molte aziende leader potrebbero preferire l'acquisizione da parte di grandi aziende farmaceutiche piuttosto che perseguire offerte pubbliche iniziali (IPO). Questa tendenza riflette un clima di investimento selettivo e un cambiamento strategico nel modo in cui le aziende biotech affrontano la crescita e il finanziamento.

Biotech M&A Set for Strongest Year Since Pre-Pandemic as Deal Value Reaches $106 Billion in 2026

06/03/2026, 11:30 PM business review biotech healthcare

The biopharma sector is experiencing a significant surge in mergers and acquisitions, with 2026 poised to become the strongest year since before the pandemic, driven by patent expirations and a favorable market environment.

Abivax (ABVX) Shares Plunge Over 30% Following Update on Bowel Disease Drug Trial

06/02/2026, 12:31 AM stock_drop biotech

Abivax is strategically planning to raise funds following the release of crucial trial data, indicating its intent to remain independent amid ongoing takeover speculation, which has significantly influenced its stock performance.

Innovent Biologics (1801.HK) Shares Surge 10% Following $10.5 Billion Partnership with Pfizer

05/28/2026, 08:32 PM announcement biotech

Innovent Biologics has entered a strategic partnership with Pfizer, which is expected to enhance its oncology drug development capabilities.

Analysts BTIG initiate coverage of Absci Corporation (ABSI) with a buy rating and $9 price target, citing potential for ABS-201 in hair loss treatment

05/28/2026, 07:33 AM investing rating_growth Analysts: analysts, BTIG biotech

Absci Corporation's innovative hair loss treatment, ABS-201, has garnered a buy rating from BTIG, with a projected peak sales potential of $2.2 billion, indicating significant market opportunity in a largely underserved sector.

Analysts Goldman Sachs initiate coverage of Hemab Therapeutics (HEMA) with Buy rating and $36 target price, citing potential for unique bleeding disorder treatment

05/26/2026, 07:32 AM investing rating_growth Analysts: analysts, Goldman Sachs biotech

Hemab Therapeutics is positioned for significant growth following its IPO, driven by its development of unique treatments for rare bleeding disorders, as highlighted by Goldman Sachs' bullish outlook.

U.S. Promotes AI Technology in Asia Following Trump-Xi Meeting

05/22/2026, 05:34 AM business announcement ai biotech

The U.S. is intensifying efforts to promote American technology, particularly in artificial intelligence, in Asia amid competition with China, which is developing its own alternatives. This strategic push follows a recent meeting between Presidents Trump and Xi, highlighting the importance of U.S. tech in the region.

Biotech and Real Estate Sectors Show Mixed Performance Ahead of Key Oncology Meeting

05/21/2026, 04:32 PM investing review biotech real_estate

The upcoming meeting of the American Society of Clinical Oncology is poised to influence biotech stocks, which have shown significant gains over the past year despite recent fluctuations. Additionally, a substantial government investment in quantum computing has sparked notable stock increases in that sector.

Topic: biotech